ArticleBMC urology2026
Effects of dutasteride with Bacillus Calmette-Guérin therapy on recurrence, progression, metastasis, and survival in non-muscle invasive bladder cancer: a retrospective single-center study.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the impact of dutasteride, a 5-alpha reductase inhibitor, used alongside intravesical Bacillus Calmette-Guérin therapy on recurrence, progression, metastasis, and disease-free survival in non-muscle invasive bladder cancer patients.
methodsA retrospective analysis was conducted on 514 male non-muscle invasive bladder cancer patients treated at a tertiary care Urology Clinic from January 1, 2015, to January 1, 2023. All participants received intravesical Bacillus Calmette-Guérin therapy induction therapy weekly for six weeks post-transurethral bladder tumor resection, followed by maintenance therapy. Sociodemographic data were collected, and patients were divided into dutasteride users and non-users. Propensity Score Matching minimized group differences. Survival times were assessed using the Kaplan-Meier method, and Cox regression models were applied for further analysis.
resultsOf the 514 patients, 257 used dutasteride. Median follow-up time was 67 months (IQR: 48–89 months). Dutasteride users were associated with significantly improved disease-free survival, recurrence-free survival, and progression-free survival (all p < 0.001). Metastasis incidence was significantly lower in dutasteride users (p < 0.001). Incidental bladder cancer detection rates during BPH assessment were similar between groups (28.4% vs. 28.4%).
conclusionsDutasteride use, in conjunction with transurethral bladder tumor resection and Bacillus Calmette-Guérin therapy, is associated with improved survival outcomes and reduced metastasis risk in non-muscle invasive bladder cancer patients, suggesting its potential as an adjuvant therapeutic option.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.